B+
Bull case
25%
Probability
Target price
$1.35
+93.6% vs current
RANI
Rani TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$0.75
+7.6% vs current
B-
Bear case
25%
Probability
Target price
$0.25
-64.1% vs current
AI sentiment snapshot
Latest data as of 2026-07-14
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+56.9
Score
AI commentary
Primary-source evidence is strong, but recent news, analyst revisions, options data, short-interest data, employee sentiment and social coverage are unavailable or insufficient. Deterministic scoring remains directionally positive, but the setup is best treated as cautious monitoring centered on clinical execution, partner milestones and runway.
RankAlpha Sentiment Codex - 2026-07-14
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31catalystChugai collaboration milestone conversionHigh impact
The company highlighted a collaboration and license agreement with Chugai worth up to $1.085 billion, providing external validation of the RaniPill platform. Value realization depends on technical progress, milestones and partner decisions [#SEC-8K-2026-03-26].
2027-06-30catalystRunway and financing visibilityHigh impact
Rani reported $43.4 million of cash, cash equivalents and marketable securities at March 31, 2026 and indicated funding into Q4 2027 including an expected Chugai technology-transfer milestone. This reduces near-term distress risk but remains sensitive to milestone timing, burn and future dilution [#SEC-8K-2026-05-15].
2027-12-31eventRT-114 Phase 1 executionHigh impact
Rani reported continued advancement of the ongoing Phase 1 RT-114 oral GLP-1/GLP-2 study with ProGen. Clinical execution, including safety, tolerability and pharmacokinetic evidence, remains the central value inflection for this micro-cap biotech [#SEC-8K-2026-05-15].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-14 • Updated nightlySource: Internal modelMethodology